Sulfadiazine is an antibacterial prescription medicine approved by the U.S. Food and Drug Administration (FDA) to prevent and treat certain types of bacterial infections, including treatment of chancroid (a sexually transmitted infection), Toxoplasma gondii encephalitis (also called toxoplasmosis), urinary tract infections, and others.
Toxoplasma gondii encephalitis is an opportunistic infection. An opportunistic infection is an infection that occurs more frequently or is more severe in people with weakened immune systems—such as those infected with HIV—than in people with healthy immune systems.
The Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, prepared by the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association of the Infectious Diseases Society of America (IDSA-HIVMA), includes recommendations on the HIV-related use of sulfadiazine to treat Toxoplasma gondii encephalitis and to prevent Toxoplasma gondii encephalitis from recurring (called secondary prophylaxis or maintenance therapy).
Before taking sulfadiazine, tell your health care provider:
Ask your health care provider about possible side effects from sulfadiazine. Your health care provider will tell you what to do if you have side effects.
Take sulfadiazine according to your health care provider’s instructions. Your health care provider will tell you how much sulfadiazine to take and when to take it. Before you start sulfadiazine and each time you get a refill, read any printed information that comes with your medicine.
More information about sulfadiazine is available:
Last Reviewed: May 7, 2013
Last Updated: May 7, 2013